Literature DB >> 9423833

The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro.

M Theisen1, S Soe, C Oeuvray, A W Thomas, J Vuust, S Danielsen, S Jepsen, P Druilhe.   

Abstract

Monocyte-dependent as well as direct inhibitory effects of antimalarial antibodies point toward antigens accessible at the time of merozoite release as targets for biologically active antibodies capable of mediating protection against Plasmodium falciparum. The glutamate-rich protein (GLURP), being an antigen associated with mature schizont-infected erythrocytes, was therefore the object of the present investigation, in which we analyzed whether anti-GLURP antibodies can either interfere directly with merozoite invasion or act indirectly by promoting a monocyte-dependent growth inhibition, antibody-dependent cellular inhibition. GLURP-specific human immunoglobulin G (IgG) antibodies, from pooled IgG of healthy Liberian adults who were clinically immune to malaria, were purified by affinity chromatography on columns containing R0 (N-terminal nonrepetitive region of GLURP) or R2 (C-terminal repetitive region of GLURP) recombinant protein or synthetic peptides as ligands. Analysis of the pattern of reactivity of highly purified anti-GLURP antibodies led to the definition of at least four B-cell epitopes. One epitope was specific for R0, two were specific for R2, and the fourth displayed cross-reactivity between R0 and R2. None of the purified IgG antibodies had direct invasion-inhibitory effects, even at high concentrations. In contrast, when allowed to cooperate with monocytes, all anti-GLURP IgG preparations mediated a strong monocyte-dependent parasite growth inhibition in a dose-dependent manner.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9423833      PMCID: PMC107852     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Fast immunopurification of small amounts of specific antibodies on peptides bound to ELISA plates.

Authors:  K Brahimi; J L Pérignon; M Bossus; H Gras; A Tartar; P Druilhe
Journal:  J Immunol Methods       Date:  1993-06-04       Impact factor: 2.303

Review 2.  Mechanisms of defense against P. falciparum asexual blood stages in humans.

Authors:  P Druilhe; J L Pérignon
Journal:  Immunol Lett       Date:  1994-07       Impact factor: 3.685

3.  Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus.

Authors:  M Theisen; G Cox; B Høgh; S Jepsen; J Vuust
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

4.  Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli.

Authors:  M Theisen; J Vuust; A Gottschau; S Jepsen; B Høgh
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

5.  Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites.

Authors:  D J McColl; A Silva; M Foley; J F Kun; J M Favaloro; J K Thompson; V M Marshall; R L Coppel; D J Kemp; R F Anders
Journal:  Mol Biochem Parasitol       Date:  1994-11       Impact factor: 1.759

6.  Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum.

Authors:  S Khusmith; P Druilhe
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

7.  The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal.

Authors:  J F Trape; C Rogier; L Konate; N Diagne; H Bouganali; B Canque; F Legros; A Badji; G Ndiaye; P Ndiaye
Journal:  Am J Trop Med Hyg       Date:  1994-08       Impact factor: 2.345

8.  Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction.

Authors:  E Bottius; A Guanzirolli; J F Trape; C Rogier; L Konate; P Druilhe
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jan-Feb       Impact factor: 2.184

9.  Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan.

Authors:  C Roper; I M Elhassan; L Hviid; H Giha; W Richardson; H Babiker; G M Satti; T G Theander; D E Arnot
Journal:  Am J Trop Med Hyg       Date:  1996-04       Impact factor: 2.345

10.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.

Authors:  H Bouharoun-Tayoun; C Oeuvray; F Lunel; P Druilhe
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  59 in total

1.  Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response.

Authors:  P V Lalitha; Lisa A Ware; Arnoldo Barbosa; Sheetij Dutta; J Kathleen Moch; J David Haynes; Bader B Fileta; Charles E White; David E Lanar
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

2.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Authors:  Suman Mazumdar; Paushali Mukherjee; Syed Shams Yazdani; S K Jain; Asif Mohmmed; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

4.  Genetic Diversity of the Plasmodium falciparum Glutamate-Rich Protein R2 Region Before and Twelve Years after Introduction of Artemisinin Combination Therapies among Febrile Children in Nigeria.

Authors:  Christian N Nguetse; Johnson Adeyemi Ojo; Charles Nchotebah; Moses Nkechukwu Ikegbunam; Christian G Meyer; Bolaji N Thomas; Thirumalaisamy P Velavan; Olusola Ojurongbe
Journal:  Am J Trop Med Hyg       Date:  2018-01-18       Impact factor: 2.345

5.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2.

Authors:  Christopher G Adda; Christopher A MacRaild; Linda Reiling; Kaye Wycherley; Michelle J Boyle; Vivian Kienzle; Paul Masendycz; Michael Foley; James G Beeson; Raymond S Norton; Robin F Anders
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

7.  Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

Authors:  Issa Nebie; Amidou Diarra; Alphonse Ouedraogo; Issiaka Soulama; Edith C Bougouma; Alfred B Tiono; Amadou T Konate; Roma Chilengi; Michael Theisen; Daniel Dodoo; Ed Remarque; Samuel Bosomprah; Paul Milligan; Sodiomon B Sirima
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

Review 8.  The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Authors:  Freya J I Fowkes; Jack S Richards; Julie A Simpson; James G Beeson
Journal:  PLoS Med       Date:  2010-01-19       Impact factor: 11.069

9.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

10.  Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.

Authors:  Marco Tamborrini; Markus S Mueller; Sabine A Stoffel; Nicole Westerfeld; Denise Vogel; Francesca Boato; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.